Nanoprox

1 known investors

NanoProX develops bismuth sulfide (Bi₂S₃) nanoparticles administered intravenously before radiotherapy to selectively accumulate in tumors and amplify local radiation dose, aiming to increase tumor cell elimination per session without new equipment. The company targets oncology treatment and works with research institutions and clinical centers on preclinical and clinical translation.